Cargando…

NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens

BACKGROUND: The NVX-CoV2373-vaccine has recently been licensed, although knowledge on vaccine-induced humoral and cellular immunity towards the parental strain and variants of concern (VOCs) in comparison to mRNA-regimens is limited. METHODS: In this observational study, 66 individuals were recruite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hielscher, Franziska, Schmidt, Tina, Klemis, Verena, Wilhelm, Alexander, Marx, Stefanie, Abu-Omar, Amina, Ziegler, Laura, Guckelmus, Candida, Urschel, Rebecca, Sester, Urban, Widera, Marek, Sester, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576915/ https://www.ncbi.nlm.nih.gov/pubmed/36279695 http://dx.doi.org/10.1016/j.jcv.2022.105321

Ejemplares similares

Myopericarditis following both BNT162b2 and NVX-CoV2373
por: Ahmad, Saima, et al.
Publicado: (2022)

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens
por: Klemis, Verena, et al.
Publicado: (2022)

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
por: Heath, Paul T., et al.
Publicado: (2021)

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19
Publicado: (2022)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
por: Lyke, Kirsten E., et al.
Publicado: (2023)

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
por: Dunkle, Lisa M., et al.
Publicado: (2021)

Protein vaccine NVX-CoV2373 elicits functional T cell immunity
por: Zhou, Pengcheng
Publicado: (2022)

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
por: Schmidt, Tina, et al.
Publicado: (2021)

NVX-CoV2373, a protein-based vaccine against SARS-CoV-2 infection
por: Vohra-Miller, Sabina, et al.
Publicado: (2022)

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
por: Áñez, Germán, et al.
Publicado: (2023)

Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid(®)) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty(®))
por: Nakayama, Tetsuo, et al.
Publicado: (2023)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
por: Tian, Jing-Hui, et al.
Publicado: (2021)

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
por: Guebre-Xabier, Mimi, et al.
Publicado: (2020)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
por: Shinde, Vivek, et al.
Publicado: (2021)

Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials
por: Smith, Katherine, et al.
Publicado: (2023)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4(+) and CD8(+) T cell responses
por: Rydyznski Moderbacher, Carolyn, et al.
Publicado: (2022)

NVX-CoV2373, un vaccin à sous-unités protéiques contre l’infection au SRAS-CoV-2
por: Vohra-Miller, Sabina, et al.
Publicado: (2022)

A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax(®)) COVID-19 Vaccination
por: Kim, Hyung Yoon, et al.
Publicado: (2022)

Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over
por: Kim, Seontae, et al.
Publicado: (2023)

Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19
por: Mateo-Urdiales, Alberto, et al.
Publicado: (2023)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
por: Gorman, Matthew J., et al.
Publicado: (2021)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
por: Bhiman, Jinal N., et al.
Publicado: (2023)

Transient Positive SARS-CoV-2 PCR without Induction of Systemic Immune Responses
por: Gärtner, Barbara C., et al.
Publicado: (2023)

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination
por: Alter, Galit, et al.
Publicado: (2021)

Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals
por: Choi, Min Joo, et al.
Publicado: (2023)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
por: Mueller-Enz, Magdalena, et al.
Publicado: (2023)

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
por: Heath, Paul T, et al.
Publicado: (2022)

Serological response to Nuvaxovid (NVX-CoV2373) vaccine given as a fifth dose in non- and low-responder kidney transplant recipients
por: Nowak, Alexandra, et al.
Publicado: (2023)

Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico
por: Áñez, Germán, et al.
Publicado: (2023)

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M(™) vaccination
por: Gorman, Matthew J, et al.
Publicado: (2021)

Differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination
por: Ziegler, Laura, et al.
Publicado: (2023)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
por: Formica, Neil, et al.
Publicado: (2021)

High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19
por: Schub, David, et al.
Publicado: (2020)

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study
por: Kulkarni, Prasad S., et al.
Publicado: (2023)

Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase
por: Macías Saint-Gerons, Diego, et al.
Publicado: (2023)

NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial
por: Marchese, Anthony M., et al.
Publicado: (2023)

Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants
por: Parums, Dinah V.
Publicado: (2022)

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
por: Puranik, Arjun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o6s6tvn2antb6sb5lf7hhrlutr